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Abstract
Background: Distortion of iron homeostasis may contribute to the pathogenesis of human immunodeficiency virus (HIV)
infection and tuberculosis (TB). We studied the association of the central iron-regulatory hormone hepcidin with the severity
of HIV and the association between hepcidin and other markers of iron homeostasis with development of TB.
Methods: Three groups of patients were selected from a prospective cohort of HIV-infected subjects in Bandung, Indonesia.
The first group consisted of HIV-infected patients who started TB treatment more than 30 days after cohort enrollment
(cases). The second group consisted of HIV-infected patients who were matched for age, gender and CD4 cell count to the
cases group (matched controls). The third group consisted of HIV-infected patients with CD4 cell counts above 200 cells/
mm3 (unmatched controls). Iron parameters including hepcidin were compared using samples collected at cohort
enrollment, and compared with recently published reference values for serum hepcidin.
Results: A total of 127 HIV-infected patients were included, 42 cases together with 42 matched controls and 43 unmatched
controls. Patients with advanced HIV infection had elevated serum hepcidin and ferritin levels. Hepcidin levels correlated
inversely with CD4 cells and hemoglobin. Cases had significantly higher hepcidin and ferritin concentrations at cohort
enrollment compared to matched controls, but these differences were fully accounted for by the cases who started TB
treatment between day 31 and 60 after enrollment. Hepcidin levels were not different in those with or without hepatitis C
infection.
Conclusion: Iron metabolism is distorted in advanced HIV infection with CD4 cell counts correlating inversely with serum
hepcidin levels. High serum hepcidin levels and hyperferritinemia were found in patients starting TB treatment shortly after
cohort enrollment, suggesting that these parameters have a predictive value for development of manifest TB in HIV-infected
patients.
Citation: Wisaksana R, de Mast Q, Alisjahbana B, Jusuf H, Sudjana P, et al. (2013) Inverse Relationship of Serum Hepcidin Levels with CD4 Cell Counts in HIV-
Infected Patients Selected from an Indonesian Prospective Cohort Study. PLoS ONE 8(11): e79904. doi:10.1371/journal.pone.0079904
Editor: Patrick C.Y. Woo, The University of Hong Kong, China
Received July 20, 2012; Accepted October 2, 2013; Published November 11, 2013
Copyright:  2013 Wisaksana et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the European Commisssion (SANTE/2005/105-033). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rudiw98@gmail.com
Introduction
Alterations in iron distribution are common in infectious
diseases and many of these alterations may be attributable to
actions of the iron-regulatory hormone hepcidin [1]. Hepcidin
degrades the sole cellular iron exporter ferroportin leading to
reduced iron absorption in the intestine and iron retention in
monocytes and macrophages and the spleen [2].
Changes in iron homeostasis have been described in HIV-
infected patients. Epidemiological studies have found an associa-
tion between elevated iron status, HIV progression and the risk for
opportunistic infections [3,4]. HIV replication involves several
iron-dependent steps [5,6], and as a central determinant of
macrophage iron contents, hepcidin may play a distinct role in
HIV pathogenesis. Indeed, hepcidin was recently shown to
increase HIV-1 transcription in cultured monocytes and T-cells
by degradation of ferroportin with a secondary increase in
intracellular iron [7]. Hepcidin may also be involved in two
important complications of human immunodeficiency virus
infection/acquired immune deficiency syndrome (HIV/AIDS).
First, elevated hepcidin levels limit iron supply to the bone
marrow. This may contribute to HIV-associated anemia, which is
a common complication of advanced HIV infection with negative
impact on clinical outcome and quality of life [8–11]. Second,
hepcidin-mediated iron accumulation in macrophages may
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increase the risk for outgrowth of intracellular pathogens like
Mycobacterium tuberculosis. Worldwide, tuberculosis (TB) is the most
important infectious disease complication among HIV-infected
patients, and several lines of evidence suggest that macrophage
iron content is related to the risk for developing active TB [12,13].
Interestingly, hepcidin itself has antibacterial activity and hepcidin
was shown to inhibit M. tuberculosis growth in vitro [14].
Data on hepcidin levels in HIV infected patients are rarely
reported and were found to be related to ferroportin mutations
(15). Apart from that, the pro-inflammatory cytokine interleukin
(IL)-6 is a dominant regulator of hepatic hepcidin production in
bacterial infections and other inflammatory conditions, but IL-6
concentrations are often only mildly elevated in viral infections.
Indeed, recent studies have shown that hepcidin levels are reduced
in hepatitis C virus (HCV) infection, which may contribute to
pathological liver iron storage in patients with chronic HCV
infection [16,17].
The present study was performed in Indonesia, which has one
of the fastest growing HIV epidemics in Asia with a high rate of
TB and hepatitis C co-infection. Our primary aim was to study the
effect HIV infection on serum hepcidin levels and other markers of
iron homeostasis and to compare hepcidin levels with recently
determined reference levels for hepcidin in healthy Dutch
volunteers [18]. The secondary aim was to identify whether
hepcidin and other markers of iron homeostasis were associated
with development of TB more than 30 days after inclusion in the
study. Finally, we studied whether iron parameters were
influenced by factors such as gender, anemia, the use and kind
of antiretroviral treatment (ART) and HCV co-infection.
Methods
Patients and setting
This study was designed as a nested case control study in a
cohort of HIV-infected patients in Hasan Sadikin Hospital in
Bandung, the referral hospital for HIV care in West-Java (11).
Free anti-retroviral treatment (ART) is delivered since December
2004. Following the 2006 World Health Organization (WHO)
guidelines [19], indications for start of ART during the study
period were: a) HIV stage IV irrespective of CD4 cell count; b)
HIV stage III with a CD4 cell count below 350 cells/mm3; and c)
HIV stage I or II with a CD4 cell count less than 200 cells/mm3.
First-line ART includes the nucleoside reverse transcriptase
inhibitors (NRTI’) zidovudine, stavudine and lamivudine, and
the non-nucleoside reverse transcriptase inhibitors (NNRTI’)
efavirenz and nevirapine.
Starting in September 2007, all patients, aged 14 years and
above are being enrolled in a prospective cohort study. Baseline
enrollment consists of a structured interview, physical examina-
tion, chest X-ray and blood examination with storage of serum at
280uC. The latter is performed within one week from initial
presentation and enrollment in the cohort. Injecting drug use is an
important route of HIV transmission in West Java and HCV
serostatus is determined in all patients. At the start of the cohort in
2007, some of the enrolled patients were already under treatment
in Hasan Sadikin hospital or another hospital. Following their
enrollment in the cohort, patients were scheduled for monthly
follow up visits.
At time of enrollment in the cohort, all HIV-infected patients
are screened for active TB by assessment of symptoms, chest X-
ray, and sputum microscopy when indicated. The diagnosis of TB
follows national and WHO guidelines, which are based on a
combination of clinical features, imaging studies and sputum acid-
fast bacilli (AFB) smear. For research purposes, M. tuberculosis
genotyping has been done in this setting using spoligotyping as
previously described, revealing nontuberculous mycobacteria in
,1% of patients [20]. For this study, sputum smear-positive
pulmonary TB was defined as at least one sputum smear positive
for acid fast bacilli (AFB). Sputum smear-negative pulmonary TB
as a chest X-ray finding consistent with tuberculosis together with
a lack of response to a trial of broad-spectrum antibiotics and at
two or more negative AFB sputum smears, including early
morning samples. Extra pulmonary TB was defined as a positive
AFB smear or culture from appropriate biopsy material,
histopathological findings consistent with tuberculosis, or clinical
signs and symptoms consistent with extra-pulmonary tuberculosis
[21]. For this study we only included patients who either had
bacteriologically proven TB, or a clear response to TB treatment.
From September 2007 until August 2010, 1323 HIV-infected
patients aged 14 years old and above entered the cohort. Patients
with signs or symptoms of an opportunistic infection or abnormal
Chest X-ray at the time of cohort enrollment (n = 516) and
patients who started on anti-TB treatment within one month after
cohort enrollment (n = 9) were excluded from this study. From the
remaining 798 patients, 45 developed TB more than 1 month after
cohort enrollment and 42 of them were included as cases in this
study. The remaining three patients were excluded because no
serum samples were available from them. The one-month interval
was deliberately chosen to avoid delayed diagnosis of co-existing
subclinical TB that might already have been present at time of
cohort enrollment. Two control groups of HIV-infected patients
without a previous diagnosis of TB and without TB during follow
were selected from the remaining 753 patients of our prospective
HIV cohort: one group matched for age, gender and CD4 cell
count (‘matched controls’; n = 42), and one control group
consisting of only moderately immunocompromised HIV-patients
with a CD4 cell count .200 cells/mm3 (‘unmatched controls’;
n = 43). From all included patients, a total number of 38 out of 127
(30%) were already on ART with a median duration of 455 days
(IQR 75-1008 days). All participants provided written informed
consent to participate in this study. This study was approved by
the Hasan Sadikin Hospital ethical committee.
Laboratory methods
Serum hepcidin and iron parameters were measured in
archived serum collected at time of cohort enrollment in the
Department of Laboratory Medicine of the Radboud University
Medical Centre using a combination of weak cation exchange
chromatography and time-of-flight mass spectrometry (TOF MS).
This technique allows discrimination between the three naturally
occurring isoforms of hepcidin (hepcidin-20, -22, and -25), of
which only the 25 amino acid form can block the iron transporter
ferroportin and is referred to as ‘‘bioactive’’ hepcidin. An internal
standard (synthetic hepcidin-24; Peptide International Inc.) was
used for quantification [22,23]. Peptide spectra were generated on
a Microflex LT matrix-enhanced laser desorption/ionization TOF
MS platform (Bruker Daltonics). Serum hepcidin-25 (further
referred to as hepcidin) concentrations were expressed in
nanomoles. The lower limit of detection of this method was
0.5 nM; average coefficients of variation were 2.7% (intra-run)
and 6.5% (inter-run). The median level of serum hepcidin-25
concentrations in healthy Dutch male adults is 4.5 nM, while the
reference range (P2.5–P97.5) is ,0.5–14.7 nM; for premenopaus-
al women these values are 2.0 nM (,0.5–12.3) [17,24].
Serum concentrations of total iron, total iron binding capacity
(TIBC), transferrin saturation (TS), ferritin, sTfR and C-reactive
protein (CRP) were determined as described previously [25]. The
following reference ranges were used: serum iron: 10–25 mmol/L;
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transferrin saturation (TS): 30–60%; total iron binding capacity
(TIBC): 45–80 mmol/L: serum ferritin: 15–280 mg/L for males
and 6–80 mg/L for premenopausal females; soluble transferrin
receptor (sTfR): 0.76–1.76 mg/L. For statistical analyses, the
lower limit of detection for CRP (5 mg/L) was used in samples
with values below this detection limit. A full blood count was
measured on a Cell Dyne 3000 (Abbot) hematology analyzer.
Anemia was defined according to World Health Organization/
AIDS Clinical Trial Group (WHO/ACTG) criteria as a hemo-
globin level below 13.0 g/dL for men and below 12.0 g/dL for
women. Anti-hepatitis C antibodies were tested by an electro-
chemiluminescence assay (ECLIA; Elecsys, Roche Diagnostics);
CD4-cell counts were determined by flow cytometry (BD
Biosciences, Jakarta, Indonesia). Due to limited volume of
archived samples, serum levels of ferritin and sTfR were available
in only 107 patients and serum iron, TIBC, TS and CRP in 38
patients.
Data analysis and statistics
Serum concentrations of hepcidin and other markers of iron
homeostasis were compared between cases and the two control
groups. Subsequently, the effect of HIV infection on iron
homeostasis was analyzed by comparing iron parameters in
matched and unmatched controls with recently determined
reference levels of serum hepcidin and by determination of the
correlation of serum hepcidin levels with CD4 cell count. Finally,
in the whole group of HIV-infected patients, associations were
examined between iron parameters and gender, anemia, ART and
the presence of HCV antibodies. Data are presented as medians
with interquartile range (IQR) unless otherwise stated. Paired
analysis for cases and the matched control group was performed
using the Wilcoxon signed-rank test for continuous variables and
the Mc Nemar test for categorical variables. Unpaired compar-
isons between cases and unmatched controls and between
matched and unmatched controls were performed using the
Mann-Whitney test and Chi-squared used. Comparison of median
hepcidin levels in our study population with reference values was
performed using the Wilcoxon signed-rank sum test. A two-sided P
value of less than 0.05 was considered statistically significant. All
statistical analyses were done by software SPSS version 17.0.
Results
Patient characteristics
A total number of 127 HIV-infected patients were included in
our study: 42 cases who developed TB during follow-up and two
control groups, consisting of 42 controls matched to cases for age,
sex and CD4 cell count (‘matched controls’), and 43 unmatched
controls with a CD4 cell count of more than 200 cells/mm3
(‘unmatched controls’). The majority of cases and matched
controls had an advanced HIV infection with a median CD4 cell
count of 30 cells/mm3 and 70 cells/mm3, respectively; the
unmatched controls were moderately immunocompromised with
a median CD4 cell count of 365 cells/mm3. Matched analysis did
not found any difference between cases and matched control
group for age, sex and CD4. Table 1 summarizes clinical and
routine laboratory characteristics in study subjects at the time of
cohort enrollment. In the cases, TB treatment was started at a
median of 125 days (IQR 44–238 days) after cohort enrollment.
Thirty-three patients (78%) of the cases had pulmonary TB;
including 12 patients with AFB smear positive TB. Patients
without bacteriological confirmation had a good response to TB
treatment (by definition). Nine patients were diagnosed with extra-
pulmonary TB of whom seven with lymphadenitis. The diagnosis
of extra-pulmonary TB was made by histopathology examination
in three cases and by a combination of clinical and radiological
features, combined with a good response to anti-TB treatment in
the remaining six. Ten of the cases had a history of TB-treatment,
a median of 512 days (IQR 357–587 days) before enrollment
which only one case did not finished 6 months TB treatment due
to side effect. By definition, the patients in the control groups had
neither a history of TB, nor any signs or symptoms suggesting
development of active TB. After cohort enrollment, 27 out of 31
cases and 20 out of 31 matched controls initiated ART. CRP levels
were only moderately elevated and mostly limited to the severely
immunocompromised patients in the cases and matched controls
group.
Iron parameters in relation to HIV status and CD4 cell
count
Median serum hepcidin levels in the whole group of HIV-
infected patients were above reference values for healthy Dutch
adult males (7.3 vs. 4.5 nM; p,0.001) and premenopausal females
(3.1 vs. 2.0 nM; p= 0.028) [16,22]. However, these higher
hepcidin were largely restricted to cases and matched controls,
i.e. those with advanced HIV infection (table 2). The unmatched
male controls had a similar median hepcidin level value as healthy
Dutch adults (4.4 [2.1–8.1] nM), but female unmatched controls
had a higher median hepcidin level (4.4 [1.5–8.2] nM). The
higher hepcidin levels in cases compared to unmatched controls
were associated with higher serum levels of the iron storage protein
ferritin and lower serum iron, TIBC and mean corpuscular
volume (MCV) values (table 2). Serum hepcidin levels also
correlated inversely with CD4 cell counts, hemoglobin levels and
MCV, and positively with serum ferritin levels (Fig. 1A–D).
Iron parameters and development of TB
Compared to matched controls, cases starting TB treatment
(‘cases’) more than 30 days after enrollment had significantly
higher serum hepcidin (p = 0.035) and ferritin levels
(p = 0.006)(Table 2). However, this difference was fully accounted
for by the cases starting TB treatment between day 31 and 60.
Compared to those starting TB treatment more than 60 days after
cohort enrollment, the cases had significantly higher serum
hepcidin and ferritin levels at cohort enrollment with median
(IQR) serum levels for hepcidin of 16.1 nM (8.4–20.6 nM) vs.
5.8 nM (4.1–14.1 nM; p= 0.01) and for ferritin of 1206 mg/l
(591–1799 mg/l) vs. 310 mg/l (190–887 mg/l; p = 0.004), despite
the fact that clinical and radiological examination showed no signs
for TB at cohort enrollment. There were no significant differences
in either hepcidin or other iron indicators between cases starting
TB treatment more than 60 days after cohort enrollment and their
matched controls. Combining all cases of pulmonary TB, smear
positive pulmonary TB was associated with a significantly higher
serum hepcidin level at cohort enrollment than smear negative TB
(15.9 nM [13.1–21.9 nM] vs. 5.3 nM [4.1–5.5 nM] nM;
p= 0.003). In addition, cases developing extrapulmonary TB
had significantly higher ferritin levels at cohort enrollment than
cases with pulmonary TB (1351 mg/L [725–1800 mg/L] vs.
491 mg/L [193–1250 mg/L]; p = 0.03), but similar hepcidin levels
(9.4 nM [6.0–11.8 nM] vs. 11.5 nM [4.9–17.0 nM]; p= 0.47).
Other factors affecting iron parameters
Apart from HIV and/or TB infection, iron parameters may be
influenced by other factors such as gender, anemia, the use and
kind of ART and HCV co-infection. As shown in Table 3, women
had significantly lower serum hepcidin and ferritin levels than men
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(p,0.01) owing to their lower total iron stores. Second, anemic
patients had higher ferritin and hepcidin levels (p,0.001 and
p= 0.05, respectively) together with a lower value of TIBC
(p,0.001), which is consistent with anemia of chronic disease.
Third, patients taking stavudine had somewhat higher hepcidin
concentrations than those taking zidovudine, although this
difference was not statistically significant (p = 0.24). Finally,
HCV-infected patients had slightly higher serum hepcidin, ferritin
and transferrin saturation levels, although these differences were
not statistically significant.
Discussion
Different studies have shown that disturbances in iron
homeostasis and anemia are associated with advanced HIV
infection and an adverse outcome [3,4,9,26]. To our knowledge,
only one study has so far reported data on hepcidin in HIV-
infected patients. Masaisa et al. found a mutation (Q248H) in the
iron exporter ferroportin to be related to lower serum hepcidin
levels, higher ferritin levels and a higher risk for pulmonary TB
[15]. Our data show that serum hepcidin levels were increased in
Indonesian patients with advanced HIV infection. In contrast,
HIV-infected patients without TB and with CD4 cell counts above
200 cells/mm3 (unmatched controls) had similar serum hepcidin
levels as healthy Dutch adults. Inflammatory cytokines, especially
IL-6, are important inducers of hepatic hepcidin expression. Our
observation of an inverse relation of CD4 cell counts with serum
hepcidin levels and the fact that elevated CRP levels were more
common in those with advanced HIV-infection support the notion
that elevated hepcidin levels in advanced HIV are predominantly
caused by HIV-associated inflammation. Moreover, only few of
the unmatched controls with CD4 cell counts above 200 cells/
mm3 had an elevated CRP level (6.7%), and this may explain why
this group had similar hepcidin levels as healthy Dutch individuals.
Other HIV-specific mechanisms, apart from inflammation, may
also contribute to higher hepcidin levels. HIV can directly infect
bone marrow progenitor cells leading to bone marrow suppres-
sion, which is associated with upregulated hepcidin expression
[27,28]. Zidovudine is also known for its suppressive effect on the
bone marrow, but use of zidovudine was not associated with
higher hepcidin levels in our study.
Our finding of increased hepcidin expression with secondary
iron dysregulation in advanced HIV infection may have several
clinical consequences. First, increased hepcidin expression leads to
macrophage iron loading and this may be associated with a higher
risk for intracellular infections. M. tuberculosis intracellular growing
bacterium that needs iron for its multiplication, and macrophage
iron loading might thus stimulate development of TB. In our
present study, we indeed found higher serum hepcidin and ferritin
levels at cohort enrollment in those who subsequently started TB
Table 1. Characteristics of HIV-infected patients who were diagnosed with tuberculosis after cohort enrollment and control
groups.
Casesa Matched controls Pb Unmatched controls Pc Pd
n=42 n=42 n=43
Age, years 29 (26–33) 30 (28–32) 0.51e 27 (25–29) 0.03 0.002
Male, % 90.5 90.5 1.00f 76.7 0.95 0.95
BMI, kg/m2 18.5 (16.9–21.1)34 18.1 (17.3–20.2)30 0.73 20.5 (18.8–21.8)37 0.016 0.005
Follow-up after cohort enrollment, days 836 (273–1110) 657 (68–1091) 0.257 539 (55–1095) 0.20 0.91
ART at baseline, % 28.6 26.2 0.81 34.9 0.53 0.38
History of TB treatment before initial visit, % 23.8 0 - 0 -
CD4 cell count, cells/mm3 30 (14–138) 70 (27–137) 0.50e 365 (324–461) ,0.001 ,0.001
CD4 cell count ,200 cells/mm3 81.0 90.5 0.21 0 ,0.001 ,0.001
Hemoglobin, g/dL 12.0 (10.1–14.1) 13.7 (12.1–14.6) 0.02 14.5 (12.9–15.3) ,0.001 0.02
Anemia, %1 63.4 38.1 0.02 14.0 ,0.001 0.01
C-reactive protein, mg/L 16.0 (5.0–36.0)7 5.0 (5.0–15.5)16 0.21 5.0 (5.0–5.0)15 0.02 0.20
C-reactive protein .10 mg/L, % 57.1 37.5 0.38 6.7 0.009 0.04
Alanine transaminase, IU/L 33.5 (20.0–54.5) 33.0 (20.8–66.0) 0.90 47.0 (21.0–69.0) 0.47 0.47
Random blood glucose, mg/dL 102.0 (87.3–116.5)40 92.5 (82.3–103.8)40 0.04 91.0 (86.8–98.0)38 0.03 0.76
Total cholesterol, mg/dL 158.5 (120.5–183.5)26 129.0 (111.0–167.0)19 0.30 158.0 (120.5–178.5)21 0.89 0.33
LDL, mg/dL 84.5 (63.5–114.0)26 70.0 (49.0–100.0)19 0.24 78.0 (54.5–103.5)21 0.76 0.52
Triglyceride, mg/dL 152.5 (103.0–196.0)26 145.0 (114.0–172.0)19 0.77 113.0 (96.5–154.0)21 0.13 0.11
Hepatitis C antibodies present, %{ 72.540 73.738 0.91 66.736 0.58 0.51
Data are presented as medians and interquartile range (IQR) unless stated otherwise. ART, antiretroviral therapy; BMI, body mass index; LDL, low-density lipoprotein.
The number of samples available in each group is shown in superscript after the IQR or percentage if less than total number.
aCases group: HIV-infected patients diagnosed with tuberculosis (TB) more than 1 month after cohort enrollment. Matched controls: HIV-infected patients without
diagnosis of TB before or after cohort enrollment, matched for age, gender and CD4 cell count to cases group. Unmatched controls: HIV-infected patients without
diagnosis of TB before or after cohort enrollment with CD4 cells .200 cells/mm3. P values were determined for b difference between matched controls and cases, c
between unmatched controls and cases and. d between matched and unmatched controls.
eWilcoxon signed rank test.
fMc Nemar test.
1Anemia defined as hemoglobin level ,13 g/dL for men or ,12 g/dL for women.
{Defined as positive anti-HCV antibodies.
doi:10.1371/journal.pone.0079904.t001
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treatment, but these higher levels were restricted to those starting
treatment from day 31 to 60 after enrollment. Recent studies have
shown that M. tuberculosis and mycobacterial components may also
induce hepcidin and we speculate that the presence of subclinical
TB at cohort enrollment accounted for these higher hepcidin and
ferritin levels [14,29]. Alternatively, higher hepcidin and ferritin
levels may put HIV-infected patients at an increased risk for TB
reactivation of TB immune reconstitution inflammatory syndrome
(IRIS). The latter seems less likely, because hepcidin not only
functions as an iron regulator, but also possesses antibacterial
effects. Indeed, other authors have suggested increased hepcidin
production in response to M. tuberculosis infection to represent a
host defense mechanism [14,29]. A second possible clinical
consequence of the high hepcidin levels is its effect on HIV
Figure 1. Correlation of serum hepcidin levels with hematology and iron parameters. Spearman correlation coefficient of serum hepcidin
levels with (A) CD4 cell count, (B) serum ferritin levels, (C) hemoglobin levels and (D) mean corpuscular volume (MCV).
doi:10.1371/journal.pone.0079904.g001
Table 2. Hepcidin and iron parameters at cohort enrollment in HIV-infected patients with (cases) or without (controls) incident TB.
Cases groupa Matched controls Pb Unmatched controls Pc Pd
n=42 n=42 n=43
Hepcidin, nM 9.9 (5.0–18.2) 7.2 (2.9–10.2) 0.035 4.4 (2.0–7.9) ,0.001 0.06
Ferritin, mg/l 680.5 (245.0–1439.0)34 297.0 (175.0–462.0)37 0.006 213.5 (74.3–358.0)36 ,0.001 0.09
sTfR, mg/l 1.4 (1.1–2.2)34 1.4 (1.2–1.9)37 0.61 1.3 (1.1–1.6)36 0.13 0.28
Serum iron, mmol/l 7.0 (5.0–11.0)7 10.5 (6.3–17.5)16 0.27 16.0 (10.0–27.0)15 0.03 0.13
TIBC, mmol/l 39.0 (38.0–54.0)7 51.0 (43.3–59.8)16 0.26 57.0 (49.0–66.0)15 0.03 0.08
Transferrin saturation, % 16.0 (12.0–27.0)7 24.0 (14.5–31.3)16 0.26 26.0 (16.0–47.0)15 0.15 0.51
MCV, fl 83.5 (80.3–92.5)39 85.5 (82.0–93.8) 0.53 88.0 (84.0–104.0) 0.049 0.11
MCH, pg 29.0 (26.3–32.0)39 29.0 (28.0–32.0) 0.98 30.0 (28.0–35.0) 0.14 0.14
Data depicted are median with interquartile range (IQR). TB, tuberculosis; TIBC, total iron binding capacity; sTfR, soluble transferrin receptor; MCV, mean cell volume;
MCH, mean cell hemoglobin.
Numbers of samples available in each group is shown in superscript after the IQR if less than total number.
aCases group: HIV-infected patients diagnosed with tuberculosis (TB) more than 1 month after initial visit. Matched controls: HIV-infected patients without diagnosis of
TB before or after initial visit, matched for age, gender and CD4 cell count to cases group. Unmatched controls: HIV-infected patients without diagnosis of TB before or
after initial visit not matched for age, gender and CD4 cell count to cases group. P values were determined for b difference between matched controls and cases by
using the Wilcoxon signed-rank test and c between unmatched controls and cases and d matched and unmatched controls by using the Mann-Whitney test.
doi:10.1371/journal.pone.0079904.t002
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progression. Several lines of evidence suggest that iron accumu-
lation in macrophages promotes HIV progression (reviewed in
Drakesmith et al. [5] and currently by Nekhai et al. [6]). Hepcidin
regulates macrophage iron content by binding to and degrading
the sole iron exporter ferroportin [2], and a recent ex vivo study
showed that hepcidin increases HIV transcription [7]. Chronic
inflammation with prolonged hepcidin over-expression may thus
explain earlier findings of a positive correlation between the degree
of iron loading in macrophages and mortality [3]. Third, hepcidin
has turned out to be a central mediator of the anemia of
inflammation by reducing iron absorption from the intestine and
iron recycling by macrophages of the spleen and the reticulo-
endothelial system. Over-expression of hepcidin in transgenic mice
indeed led to typical features of anemia of inflammation [30].
Hepcidin can also directly inhibit red blood cell production during
inflammation [31]. Anemic patients in our study had significantly
higher hepcidin levels and there was a negative correlation of
hepcidin levels with hemoglobin levels. Thus, prolonged HIV-
associated changes in absorption and distribution of iron through
the actions of hepcidin are likely to contribute to the still poorly
understood anemia of advanced HIV infection. For clinical
management of anemic HIV-infected patients, our data suggest
that iron supplementation will be of limited benefit as the elevated
hepcidin levels compromise iron absorption. Serum hepcidin may
prove a useful parameter to select those patients with absolute iron
deficiency who may benefit from iron supplementation.
Serum ferritin levels were strongly elevated in patients who
developed tuberculosis 31–60 days after enrollment. Several
mechanisms may explain the high ferritin level in these patients.
First of all, ferritin is an acute phase protein and inflammation can
independently increase ferritin expression. Unfortunately, suffi-
cient data to analyze this further were not available. Other factors
that may contribute to high ferritin levels include HIV [32],
chronic liver disease [33], metabolic syndrome or iron loading
anemia. Some of these factors do not seem relevant: increased
ferritin levels were neither noticed in control patients with an
untreated HIV infection nor in those with HCV infection.
Alcoholic liver diseases is also very rare in our Muslim population
while none of the patients was known with an iron loading anemia
or a history of recent blood transfusion. Although obesity and
hypertension are rare in our population, a trend for higher
triglyceride and random blood glucose levels was noticed in the
cases, suggesting some metabolic disturbance. A fatty liver with
hyperferritinemia can also be seen in other conditions such as
rapid weight loss, starvation, and use of illicit drugs [34].
Interestingly, a large autopsy study from India revealed that
tuberculosis was the second commonest cause of steatohepatitis
[35] and severe hyperferritinemia in Mycobacterium tuberculosis
infection has recently been reported, especially among HIV-
infected patients [36]. Our results were however not obtained from
patients with active TB but an average of 125 days earlier when no
signs of an active (opportunistic) infection were present. Possibly,
serum ferritin may thus be a useful and low-cost marker to predict
the change for development of TB in near future. Hepcidin seems
less useful for this purpose because of its high cost and limited
availability of assays.
As injecting drug use is the main route of HIV transmission in
the setting of this study, a significant proportion of patients were
also infected with HCV. Chronic HCV infection is associated with
disturbances in iron homeostasis, most prominently iron accumu-
lation in hepatocytes [37]. Two recent studies found relatively low
hepcidin levels in patients with HCV, suggesting that HCV
impairs hepcidin production, which may in turn contribute to high
iron contents of the liver [15,16]. These findings could not be
Table 3. Hepcidin, iron and inflammatory parameters in HIV-infected patients at cohort enrollment.
Characteristics Hepcidin Serum iron TIBC Transferrin Ferritin sTfR CRP
(nM) (mmol/l) (mmol/l) saturation (%) (mg/l) (mg/l) (mg/L)
Gender
Male 7.3 (4.0–13.1)109 11.5 (6.3–20.0)28 53.5 (39.0–62.8)28 27.5 (14.5–36.5)28 344 (194–795)92 1.4 (1.2–2.0)92 5.0 (5.0–16.0)28
Female 3.1 (1.5–6.9)18 a 9.5 (8.5–12.5)10 54.0 (48.5–66.8)10 17.0 (12.8–25.3)10 60 (46–132)15 a 1.5 (1.1–1.9)15 5.0 (5.0–7.3)10
Anemia
Yes 9.2 (4.6–16.4)49 9.0 (4.5–13.0)17 42.0 (38.5–49.0)17 21.0 (11.0–33.0)17 698 (257–1460)43 1.4 (1.0–2.2)43 14.0 (5.0–41.5)17
No 5.3 (2.5–9.6)78 b 16.0 (9.0–20.0)21 61.0 (55.0–66.0)21 b 26.0 (16.0–31.0)21 217 (112–351)64 b 1.4 (1.2–1.8)64 5.0 (5.0–5.0)21 b
Receive ART
Yes 5.6 (2.6–9.8)38 20.5 (9.8–36.8)9 45.5 (39.0–53.0)9 42.5 (19.0–87.0)9 290 (161–1081)32 1.7 (1.3–2.2)32 7.0 (5.0–26.5)9
ZDV containing 5.2 (2.2–9.6)26 27.0 (4.0–40.0)7 49.0 (39.0–57.0)7 47.0 (10.0–93.0)7 252 (130–741)22 1.7 (1.2–2.1)22 7.0 (5.0–14.0)7
d4T containing 7.4 (3.2–16.5)12 13.0 (12.0–14.0)2 40.5 (31.0–50.0)2 33.0 (28.0–38.0)2 431 (205–1227)10 1.8 (1.3–2.7)10 22.0 (5.0–39.0)2
No 7.2 (3.3–12.5)89 10.5 (6.8–18.0)29 55.5 (47.8–65.3)29 19.0 (13.0–28.3)29 c 301 (166–608)75 1.3 (1.1–1.7)75 b 5.0 (5.0–12.5)29
HCV
Yes 6.8 (3.0–11.6)80 11.0 (6.0–11.0)19 55.0 (39.0–64.0)19 27.0 (16.0–32.0)19 298 (191–596)66 1.3 (1.1–1.9)66 5.0 (5.0–16.0)19
No 5.8 (2.5–13.1)33 9.0 (7.0–12.0)11 50.0 (44.0–56.0)11 16.0 (13.0–25.0)11 257 (84–698)29 1.5 (1.2–2.2)29 5.0 (5.0–14.0)11
Data are based on 127 HIV-infected patients belonging to case group and the matched and unmatched control groups. Data depicted as median with interquartile
range. TIBC, total iron binding capacity; sTfR, soluble transferrin receptor; CRP, C-reactive protein; ART, antiretroviral therapy; HCV, hepatitis C; ZDV, zidovudine; d4T,
stavudine.
Hemoglobin and serum hepcidin levels were available for 127 patients; ferritin and sTfR for 107 patients and serum iron, TIBC, transferrin saturation and CRP in 38
patients, Anti HCV antibodies were available in 113 patients. Numbers of samples per groups are shown in superscript after the IQR.
ap,0.01 between male and female group;
bp,0.01 between anemia and non-anemia group;
cp,0.05 between group with and without ART.
doi:10.1371/journal.pone.0079904.t003
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confirmed in our study, which is the first study to report data in
HCV/HIV co-infected patients.
Our study has several limitations. First, in more than 50% in all
cases there was no culture confirmation of TB. Unfortunately, it is
well known that sputum microscopy and culture both suffer from
decreased sensitivity in HIV-infected individuals [38,39]. We like
to point out that we only included patients with bacteriological
proof or clinical and radiological signs of tuberculosis, plus a
positive treatment response. Second, as also mentioned above, we
cannot exclude with certainty that TB was already present in some
of the cases during cohort enrollment, even though clinical and
radiological examination failed to show any signs of active TB.
The fact that as much as 85% of cases and matched controls had a
CD4 count less than 200 cells/mm3 at cohort enrollment increases
the risk for subclinical TB. Third, development of an IRIS against
TB following the start of ART is common in this setting [40], and
some of the patients starting TB treatment may in fact have
suffered from TB IRIS. Fourth, data on serum iron, transferrin
saturation and CRP were only available in a subset of patients due
to limited volume of some of the archived samples, although no
differences in clinical characteristics were found between patients
with and without available samples (data not shown). Finally, we
acknowledge that the number of patients developing TB was
rather small despite the fact that 798 patients were prospectively
followed for a median follow-up time of 836 days (table 1). The
small sample size was also the reason for not performing a
multivariate analysis. However, we feel that none of these issues
can account for the significant associations we found between
hepcidin and CD4 cell count and development of TB.
In conclusion, our study shows that advanced HIV infection is
associated with increased hepcidin expression and characteristic
features of iron maldistribution. This may, among others,
stimulate HIV progression and contribute to HIV-associated
anemia. Patients starting TB treatment shortly after cohort
enrollment had significantly higher serum hepcidin and ferritin
level at cohort enrollment, but this effect was not present in those
starting TB treatment after at least 2 months.
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